Successful Biomedical Catalyst Funding Award

VascVersa leads consortium to advance new cell therapy for the treatment of chronic non-healing wounds.

• VascVersa, a spin-out from the Queen’s University Belfast will partner with Cell and Gene Therapy Catapult, the Scottish National Blood Transfusion Service and Queen’s University Belfast to develop its new cell therapy.

• Funding from the Innovate UK’s Biomedical Catalyst funding programme in excess of £800,000.

• VascVersa’s new cell therapy, Angicyte, promotes the creation of new blood vessels in diabetic patients.

• Diabetic Foot Ulcers costs the NHS over £1 billion a year.